Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study

Fig. 2

Time-to-first moderate/severe COPD exacerbations. The analyses were performed in the full analysis set from the FLAME study. Subjects who did not experience a COPD exacerbation were censored at the earlier date of last double-blind treatment + 1, death and final visit. Figure truncated after Week 52 (Day 365). b.i.d., twice daily; CI, confidence interval; HR, hazard ratio; IND/GLY, indacaterol/glycopyrronium 110/50 μg o.d.; o.d., once daily; SFC, salmeterol/fluticasone 50/500 μg b.i.d

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us